Sunovion Brands

LUNESTA® (eszopiclone) is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance.


Treatment Success

Bring rest into the night with LUNESTA® (eszopiclone) to help insomnia patients fall asleep and stay asleep so they can wake up feeling rested.

†In clinical studies, LUNESTA was proven effective to help the majority of insomnia patients fall asleep and stay asleep for up to 7 hours. Individual results may vary.

1. LUNESTA [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; May, 2014.
2. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979-1991.
3. Data on file, CSR 190-046. Sunovion Pharmaceuticals Inc.
4. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. SLEEP. 2003;26(7):793-799.
5. Hohagen F. Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening—temporal stability of subtypes in a longitudinal study on general practice attenders. SLEEP. 1994;17(6):551-554.
6. Data provided by Fingertip Formulary and is current as of December 2012.
7. Data provided by Symphony Health Solutions Access Investigator and reflects data collected from June to November 2012.

LUN001-15 2/15